SecBot SecBot

IOVA drug pipeline

$7.55
−2.7% 1-day · Nov 16
Next catalyst
2027
Amtagvi BLA filing
Typical move on FDA news
±46.1%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
5
5 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. 2027
    Amtagvi
    BLA filing · Second-line non-squamous metastatic non-small cell lung cancer

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved (accelerated approval)
Time to marketAlready approved and marketed (FDA accelerated approval Feb 16, 2024). Confirmatory Phase 3 (TILVANCE-301) is ongoing to convert to full approval.

Amtagvi lifileucel Updated Jul 2

2027
Next catalyst
BLA filing · 2027 · Second-line non-squamous metastatic non-small cell lung cancer
What to watch

Watch for TILVANCE-301 Phase 3 interim or topline results (undated but the key catalyst for converting accelerated to full approval and expanding into frontline) and quarterly revenue growth trajectory, Q2 2026 guidance is $86M-$88M. Also monitor IOV-LUN-202 NSCLC registrational data (Fast Track, potential launch 2H27). At ~$3.97 with a mean analyst target of $8.80 (177% upside), the stock prices in meaningful commercial execution but not a TILVANCE-301 success.

Bull case
  • First and only FDA-approved TIL therapy for solid tumors, first-mover advantage in a new treatment class (source: FiercePharma)
  • Strong commercial momentum: FY2025 product revenue of ~$264M (+61% YoY), Q4 at $87M (+30% QoQ); FY2026 guidance $350M-$370M
  • 90+ authorized treatment centers established in the US, with Australian TGA approval received June 2026 for third global market entry (source: SEC 8-K filing July 2, 2026)
Bear case
  • Accelerated approval requires confirmatory data; if TILVANCE-301 Phase 3 fails to meet endpoints, the drug could face withdrawal or label restriction, a binary risk with no hard readout date yet (source: FDA press release)
  • Complex manufacturing logistics: personalized cell therapy requires tumor harvest, centralized manufacturing, and infusion, limiting scalability vs off-the-shelf alternatives (source: FiercePharma)
  • Competition intensifying: Bristol Myers Squibb's IO triplet in melanoma and other emerging TIL/cell therapies could erode market share (source: FiercePharma, AInvest)
● neutral
Impact
PhasePhase 1/2
Time to market5+ years (Phase 1/2; furthest Phase 2 efficacy portion ongoing; regulatory filing unlikely before 2028-2029 if successful)

IOV-4001 PD-1 knockout tumor-infiltrating lymphocyte therapy Updated Jul 2

What to watch

Watch for IOV-4001 Phase 2 efficacy data from the melanoma cohort of IOV-GM1-201, which was expected in early 2026 and may be reported later this year. Positive data would validate Iovance's next-generation TIL platform and could lift the stock, but IOVA's near-term value is primarily tied to Amtagvi commercial execution. The 2026 revenue guidance of $350M-$370M and Q2 earnings (around Aug 6, 2026) are more immediate catalysts.

Bull case
  • IOV-4001 is the first gene-edited TIL therapy to enter the clinic, combining TIL efficacy with intrinsic PD-1 blockade in a single infusion, potentially eliminating the need for separate checkpoint inhibitor drugs and their systemic side effects.
  • Iovance is the leader in commercialized TIL therapy (Amtagvi was the first FDA-approved TIL for solid tumors), giving it real-world manufacturing and commercial infrastructure that competitors lack.
  • Analyst consensus is heavily bullish: 13 Buy/Strong Buy vs 3 Hold vs 0 Sell, with a mean price target of $8.80 (177% implied upside) as of July 2026.
Bear case
  • IOV-4001 is still in Phase 1/2 with no publicly reported efficacy data as of July 2026, despite the Phase 2 data having been anticipated in Q1 2026, suggesting possible delays or underwhelming interim results.
  • The TIL therapy approach requires complex, individualized manufacturing (tumor resection, cell expansion, infusion), which is slow, expensive, and limits scalability vs. off-the-shelf immunotherapies.
  • Iovance faces competition from other TIL developers (Instil Bio, Turnstone Biologics) and established checkpoint inhibitors from Merck (Keytruda) and BMS (Opdivo/Yervoy) that already dominate the melanoma and NSCLC markets.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 1992 (FDA)

Proleukin aldesleukin Updated Jul 2

What to watch

Proleukin is a steady, low-growth commercial asset for Iovance, providing ~$44M-60M in annual revenue (17% of total product sales). It functions largely as a support drug for Iovance's flagship TIL therapy Amtagvi. For IOVA investors, the stock's binary catalysts revolve around Amtagvi's label expansion (Phase 3 frontline melanoma, NSCLC), not Proleukin. Proleukin's main risk is gradual revenue erosion from newer engineered IL-2 competitors and potential biosimilar entry given its long-expired patents.

Bull case
  • Proleukin provides a steady, predictable revenue stream (~$44-60M/year) with established commercial infrastructure, contributing to Iovance's top line with no additional R&D investment required.
  • Proleukin is integral to the Amtagvi TIL therapy regimen, creating a bundled commercial strategy where growth in Amtagvi prescriptions also drives Proleukin demand.
  • The acquisition (fully paid in Jan 2023) also secured IL-2 supply for Iovance's clinical and future commercial TIL manufacturing, vertically integrating a key input.
Bear case
  • Proleukin is a mature, off-patent drug (composition patents expired early 2010s) facing eventual biosimilar competition that could erode pricing and revenue.
  • Newer engineered IL-2 therapies (PEGylated, masked, non-alpha-binding variants) from competitors aim for better tolerability and efficacy, potentially displacing native IL-2 over time.
  • Proleukin represents only ~17% of Iovance's product revenue, Amtagvi is the real value driver. IOVA stock moves on Amtagvi data and sales, not Proleukin's modest contribution.
● neutral
Impact
PhasePhase 1/2
Time to marketUnknown; currently in Phase 1 dose-finding, with Phase 2 advancement expected in 2026 at the earliest. Commercialization is likely several years away if successful.

IOV-3001 modified interleukin-2 fusion protein (IL-2 analog) Updated Jul 2

What to watch

IOV-3001 is too early-stage to drive meaningful stock movement in the near term. Iovance investors should focus on Amtagvi commercial execution, the Phase 3 TILVANCE-301 frontline melanoma readout, and catalysts from IOV-4001 and IOV-LUN-202 (NSCLC), all of which carry more weight for IOVA's share price than this early IL-2 analog program.

Bull case
  • IOV-3001 has a differentiated mechanism, a modified IL-2 fused to palivizumab antibody, that preclinical data (ASCO 2024) showed has a longer half-life and potentially better safety profile than aldesleukin, which could improve the TIL therapy patient experience and reduce hospitalization burden.
  • If successful, IOV-3001 could become the standard IL-2 component of Iovance's entire TIL platform, potentially extending to all current and future lifileucel indications (melanoma, NSCLC, endometrial cancer, sarcoma, etc.), which would broaden its addressable market beyond the current melanoma-specific trial.
  • The drug was licensed from Novartis in 2020, and Iovance has advanced it from IND to Phase 1/2 clinical trial (IND allowed to proceed in Q3 2024), demonstrating effective pipeline execution. Iovance is also manufacturing IOV-3001 via CDMO Avid Bioservices, suggesting commercial-scale planning is underway.
Bear case
  • IOV-3001 is highly early-stage (Phase 1 dose-finding with only ~42 estimated patients) and has no clinical efficacy data yet, all positive data to date is preclinical. Clinical failure or a safety signal in humans would be a significant setback.
  • The drug is a minor asset within Iovance's pipeline; the company's value is dominated by Amtagvi (already approved/commercialized), with ~$264M in product revenue in 2025. IOV-3001's contribution to IOVA's stock price is negligible in the near term.
  • Competition from other IL-2 pathway modulators (e.g., Nektar's bempegaldesleukin, Roche's IL-2 programs) and alternative approaches to improving TIL regimens could render IOV-3001's approach less differentiated by the time it reaches the market (likely years away).
● neutral
Impact
PhasePhase 1/2 (IND cleared, not yet enrolling)
Time to marketUnknown; Phase 1/2 enrollment begins H2 2026. If successful, a registrational trial and potential approval would likely be several years away (2029+).

IOV-5001 IL-12 tethered TIL therapy Updated Jul 2

What to watch

IOV-5001 is too early-stage to drive IOVA's share price in the next 12 months. Investors should focus on Amtagvi revenue growth (FY26 guidance $350M-$370M), the TILVANCE-301 Phase 3 frontline melanoma readout, and IOV-LUN-202 NSCLC registrational data as the primary value drivers. IOV-5001 is a pipeline story for 2028+.

Bull case
  • IOV-5001 is a clever engineering solution to a known problem: earlier secreted IL-12 TIL therapies showed a 63% confirmed objective response rate but caused toxicity from systemic IL-12 leakage. Tethering IL-12 to the cell surface and making expression tumor-dependent (via NFAT promoter) could retain efficacy while eliminating the toxicity.
  • The Phase 1/2 basket trial targets large, difficult-to-treat solid tumors (colorectal, triple-negative breast) where current TIL therapy hasn't been tested, representing a massive addressable market expansion beyond melanoma.
  • Iovance is the undisputed leader in TIL therapy with the only FDA-approved TIL product (Amtagvi), existing manufacturing infrastructure, and a growing commercial footprint that de-risks development and potential launch of IOV-5001.
Bear case
  • IOV-5001 has not yet treated a single patient in a clinical trial. Preclinical data (AACR 2025, SITC 2024), while promising, does not guarantee human safety or efficacy, especially since the NFAT-inducible IL-12 system is novel and unvalidated in humans.
  • The basket trial approach (multiple tumor types in one study) creates execution risk. If early safety signals differ across cohorts, the program could be delayed or require redesign.
  • Competing next-gen TIL approaches (Instil Bio's ITIL-306, Turnstone Biologics' TIL therapies) and other IL-12 delivery modalities could leapfrog IOV-5001 before its data matures.

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Aug 6, 2026AmtagviFast Track+46.1%+50.2%

Clinical trials

4 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
AmtagviStudy of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsPhase 2Terminated225Feb 20, 2026
LN-145Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaPhase 2Terminated · results210Aug 22, 2025
AmtagviLifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic MelanomaPhase 2Completed11Jul 10, 2025
AmtagviStudy of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaPhase 2Completed · results220Oct 24, 2024